229 related articles for article (PubMed ID: 26785755)
1. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.
Siebert N; Eger C; Seidel D; Jüttner M; Zumpe M; Wegner D; Kietz S; Ehlert K; Veal GJ; Siegmund W; Weiss M; Loibner H; Ladenstein R; Lode HN
MAbs; 2016; 8(3):604-16. PubMed ID: 26785755
[TBL] [Abstract][Full Text] [Related]
2. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
[TBL] [Abstract][Full Text] [Related]
4. Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N; Seidel D; Eger C; Brackrock D; Reker D; Schmidt M; Lode HN
J Immunol Methods; 2013 Dec; 398-399():51-9. PubMed ID: 24055592
[TBL] [Abstract][Full Text] [Related]
5. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
Siebert N; Troschke-Meurer S; Marx M; Zumpe M; Ehlert K; Gray J; Garaventa A; Manzitti C; Ash S; Klingebiel T; Beck J; Castel V; Valteau-Couanet D; Loibner H; Ladenstein R; Lode HN
Cancers (Basel); 2018 Oct; 10(10):. PubMed ID: 30336605
[TBL] [Abstract][Full Text] [Related]
6. Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.
Ladenstein R; Weixler S; Baykan B; Bleeke M; Kunert R; Katinger D; Pribill I; Glander P; Bauer S; Pistoia V; Michon J; Garaventa A; Lode HN
MAbs; 2013; 5(5):801-9. PubMed ID: 23924804
[TBL] [Abstract][Full Text] [Related]
7. Validated detection of human anti-chimeric immune responses in serum of neuroblastoma patients treated with ch14.18/CHO.
Siebert N; Eger C; Seidel D; Jüttner M; Lode HN
J Immunol Methods; 2014 May; 407():108-15. PubMed ID: 24727144
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R; Pötschger U; Valteau-Couanet D; Luksch R; Castel V; Yaniv I; Laureys G; Brock P; Michon JM; Owens C; Trahair T; Chan GCF; Ruud E; Schroeder H; Beck Popovic M; Schreier G; Loibner H; Ambros P; Holmes K; Castellani MR; Gaze MN; Garaventa A; Pearson ADJ; Lode HN
Lancet Oncol; 2018 Dec; 19(12):1617-1629. PubMed ID: 30442501
[TBL] [Abstract][Full Text] [Related]
9. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma.
Desai AV; Fox E; Smith LM; Lim AP; Maris JM; Balis FM
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1047-55. PubMed ID: 25212536
[TBL] [Abstract][Full Text] [Related]
11. Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
Troschke-Meurer S; Siebert N; Marx M; Zumpe M; Ehlert K; Mutschlechner O; Loibner H; Ladenstein R; Lode HN
Oncoimmunology; 2019; 8(12):1661194. PubMed ID: 31741754
[TBL] [Abstract][Full Text] [Related]
12. Functional bioassays for immune monitoring of high-risk neuroblastoma patients treated with ch14.18/CHO anti-GD2 antibody.
Siebert N; Seidel D; Eger C; Jüttner M; Lode HN
PLoS One; 2014; 9(9):e107692. PubMed ID: 25226154
[TBL] [Abstract][Full Text] [Related]
13. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
Gilman AL; Ozkaynak MF; Matthay KK; Krailo M; Yu AL; Gan J; Sternberg A; Hank JA; Seeger R; Reaman GH; Sondel PM
J Clin Oncol; 2009 Jan; 27(1):85-91. PubMed ID: 19047298
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
Sondel PM; Hank JA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients.
Uttenreuther-Fischer MM; Huang CS; Yu AL
Cancer Immunol Immunother; 1995 Dec; 41(6):331-8. PubMed ID: 8635190
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study.
Ozkaynak MF; Sondel PM; Krailo MD; Gan J; Javorsky B; Reisfeld RA; Matthay KK; Reaman GH; Seeger RC
J Clin Oncol; 2000 Dec; 18(24):4077-85. PubMed ID: 11118469
[TBL] [Abstract][Full Text] [Related]
18. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD
Siebert N; Zumpe M; Jüttner M; Troschke-Meurer S; Lode HN
Oncoimmunology; 2017; 6(10):e1343775. PubMed ID: 29123953
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
[TBL] [Abstract][Full Text] [Related]
20. Reduction of CD11b
Siebert N; Zumpe M; von Lojewski L; Troschke-Meurer S; Marx M; Lode HN
Oncoimmunology; 2020 Oct; 9(1):1836768. PubMed ID: 33150046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]